Core B-Omics and Gene-Editing

核心 B 组学和基因编辑

• 批准号: 10553866
• 负责人: MICHAEL R GARRETT
• 金额: $ 48.28万
• 依托单位: UNIVERSITY OF MISSISSIPPI MED CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-06 至 2028-02-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10553866
• 关键词: Address; Bioinformatics; Biological; Biological Assay; Biological Process; Biometry; Biostatistics Core; CRISPR/Cas technology; Cell Line; Cells; Complement; Computational Biology; Consultations; Data; Data Collection; Data Set; Development; Disease; Disease Progression; Early Intervention; Education; Enhancement Technology; Ensure; Epigenetic Process; Equipment; Extramural Activities; Faculty; Faculty Workshop; Funding; Gene Expression; Generations; Genes; Genetic Predisposition to Disease; Genetic Variation; Genome; Genomics; Genotype; Goals; Health; High-Throughput Nucleotide Sequencing; Human Resources; Infrastructure; Instruction; Investigation; Link; Lipids; Maintenance; Mass Spectrum Analysis; Measures; Mentors; Mentorship; Metagenomics; Methodology; Methods; Methylation; Mission; Molecular; Organ; Pathway interactions; Pharmaceutical Preparations; Phase; Physiological; Physiology; Pilot Projects; Process; Program Description; Proteins; Proteomics; Research; Research Personnel; Resources; Services; Students; Supervision; Systems Biology; Teacher Professional Development; Technical Expertise; Techniques; Technology; Therapeutic; Tissues; Toxin; Training; Training and Education; Transcript; Variant; Work; Xenobiotics; body system; cell type; education planning; enzyme activity; epigenetic regulation; expectation; gene function; genome sequencing; genome-wide; high throughput technology; improved; innovation; insight; instrumentation; loss of function; meetings; metabolomics; new technology; new therapeutic target; next generation sequencing; novel; programs; service delivery; small molecule; success; synergism; training opportunity; transcriptome sequencing; transcriptomics; viral vector development; whole genome

Core B-Abstract The goal of the Molecular Center of Health and Disease (MCHD) is to facilitate research under a central theme of molecular physiology to enhance the depth of education, mentorship, and training of researchers to apply omics technology and computational biology across the health-disease continuum. An understanding of genetic susceptibility and molecular mechanisms involved in onset and progression of disease has the potential to lead to early interventions as well as novel therapeutic targets. The integration of genomic, transcriptomic, proteomic, and metabolomic datasets along with physiological information using computational approaches can provide novel insight into the molecular, cellular, and overall physiology associated with the health-disease continuum. The mission of the MCHD will be achieved through synergistic interaction across multiple components, including Core A (including administrative oversight, education and mentoring programs, and a pilot project program), two research cores, and three major project investigators, to address diverse questions of health and disease using molecular and computational approaches. In particular, Core B- Omics and Gene-Editing will provide researchers access to a comprehensive state-of-the-art omics data collection pipelines, mechanistic gene- editing and biological approaches, and seamless integration with the Research Computing, Bioinformatics, and Biostatistics Core (Core C) will provide greater depth and insight into biological processes associated with major project and pilot program researcher scientific questions. Core B will enhance current infrastructure, including by implementing new high-throughput sequencing methods, such as spatial transcriptomics and new equipment for long-read sequencing and structural variation as well as the development of a new and innovative capability involving CRISPR/Cas9 gene-editing technology to interrogate gene function and biological pathways. The objectives of Core B are: (1) promote education and training of faculty, trainees, and students in omics technologies and gene-editing technologies; (2) provide MCHD investigators access to technical expertise and cutting-edge omics services, including next generation sequencing methodologies and mass spectrometry targeted proteomics and metabolomics; (3) provide MCHD investigators access to advanced gene-editing and viral vector development to investigate gene function and pathways associated with researcher initiated scientific questions; and (4) seek continuous improvement in existing assays, services, and enhance technological capabilities through acquisition of new cutting-edge instrumentation that will assist in the sustainability of the Core. In total, these aims will work in synergy with junior researchers to provide an innovative, state-of-the-art infrastructure to enhance and strengthen investigation into the molecular underpinnings of health and disease, bolster success in extramural research funding, and collaboratively grow the MCHD.

核心B-摘要 健康与疾病分子中心 (MCHD) 的目标是促进中心主题下的研究 分子生理学的研究，以提高研究人员应用的教育、指导和培训的深度 跨健康疾病连续体的组学技术和计算生物学。对遗传的理解 涉及疾病发生和进展的易感性和分子机制有可能导致 早期干预以及新的治疗目标。基因组学、转录组学、蛋白质组学的整合 使用计算方法的代谢组数据集以及生理信息可以提供 对与健康-疾病连续体相关的分子、细胞和整体生理学的新见解。 MCHD 的使命将通过多个组成部分的协同互动来实现，包括 核心 A（包括行政监督、教育和指导计划以及试点项目计划），两个 研究核心和三个主要项目研究人员，利用 分子和计算方法。特别是，核心 B 组学和基因编辑将提供 研究人员可以使用全面的、最先进的组学数据收集管道、机械基因组学 编辑和生物学方法，以及与研究计算、生物信息学和 生物统计学核心（核心C）将提供与主要相关生物过程的更深入和洞察力 项目和试点计划研究员的科学问题。核心B将增强当前的基础设施，包括 通过实施新的高通量测序方法，例如空间转录组学和新设备 用于长读长测序和结构变异以及开发新的创新能力 涉及 CRISPR/Cas9 基因编辑技术来探究基因功能和生物途径。这 核心 B 的目标是：(1) 促进组学领域教师、学员和学生的教育和培训 技术和基因编辑技术； (2) 为 MCHD 调查人员提供技术专业知识和 尖端的组学服务，包括下一代测序方法和质谱分析 靶向蛋白质组学和代谢组学； (3) 为 MCHD 研究人员提供先进的基因编辑和 病毒载体开发，用于研究与研究人员发起的科学相关的基因功能和途径 问题; (4) 寻​​求现有检测、服务的持续改进，并增强技术 通过购买新的尖端仪器来增强能力，这将有助于可持续发展 核。总的来说，这些目标将与初级研究人员协同工作，提供创新的、最先进的 加强和加强对健康和疾病的分子基础的调查的基础设施， 支持校外研究经费的成功，并共同发展 MCHD。